StockData
ADMA Biologics, Inc. logo

ADMA Biologics, Inc. (ADMA) stock

ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 16/3036% below fair value
$13.68+0.44 (+3.32%)

Close on Nov 13, 2026Market cap $3.06BP/E 17.8Yield –

Earnings

ADMA Biologics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 24, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
$141.10M
+5.1% on a year earlier
Adjusted Basic EPS, Q3 FY2026
$0.23
$0.15 a year earlier
Latest guidance
Lowered
Nov 4, 2026 · 3 items

Quarterly results

Revenue and earnings per share from each of ADMA Biologics's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 24, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 4, 2026after the close$141.10M+5.1%$0.22$0.23Release
Q2 FY2026ended Jun 30, 2026Aug 5, 2026during market hours$124.40M+2.0%$0.16–Release
Q1 FY2026ended Mar 31, 2026May 6, 2026during market hours$114.50M-0.3%$0.19–Release
Q4 FY2025ended Dec 31, 2025Feb 25, 2026during market hours$139.20M+18.5%$0.20–Release
Q3 FY2025ended Sep 30, 2025Nov 5, 2025during market hours$134.20M+12.0%$0.15–Release
Q2 FY2025ended Jun 30, 2025Aug 6, 2025during market hours$122.00M+13.8%$0.14–Release
Q1 FY2025ended Mar 31, 2025May 7, 2025during market hours$114.80M+40.2%$0.11–Release
Q4 FY2024ended Dec 31, 2024Mar 3, 2025during market hours$117.50M+59.0%$0.46–Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024during market hours$119.80M+78.0%$0.15–Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024during market hours$107.20M+78.4%$0.13–Release
Q1 FY2024ended Mar 31, 2024May 9, 2024during market hours$81.90M+43.9%$0.08–Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

ADMA Biologics's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
total revenueFY2026$530.00M$625.00MLoweredNov 4, 2026
total revenueFY2026$530.00M – $560.00M$530.00M – $560.00MReaffirmedAug 5, 2026
total revenueGAAPFY2026$635.00M–NewFeb 25, 2026
Adjusted EBITDAnon-GAAPFY2026$275.00M$360.00MLoweredNov 4, 2026
Adjusted EBITDAnon-GAAPFY2026$265.00M – $300.00M$265.00M – $300.00MReaffirmedAug 5, 2026
Adjusted Net Incomenon-GAAPFY2026$180.00M$255.00MLoweredNov 4, 2026
Adjusted Net Incomenon-GAAPFY2026$170.00M – $200.00M$170.00M – $200.00MReaffirmedAug 5, 2026
expected Adjusted Net Incomenon-GAAPFY2026$255.00M–ReaffirmedJan 12, 2026
net incomeGAAPFY2026$230.00M–NewJan 13, 2025
total revenueGAAPFY2027$775.00M–NewFeb 25, 2026
total revenueFY2027$775.00M–NewJan 12, 2026
Adjusted EBITDAnon-GAAPFY2027$455.00M–NewFeb 25, 2026
Adjusted EBITDAnon-GAAPFY2027$455.00M–NewJan 12, 2026
Adjusted Net Incomenon-GAAPFY2027$315.00M–NewFeb 25, 2026
Adjusted Net Incomenon-GAAPFY2027$315.00M–NewJan 12, 2026
total annual revenueGAAPFY2029$1.10B–NewFeb 25, 2026
total annual revenueFY2029$1.10B$1.10BReaffirmedJan 12, 2026
Adjusted EBITDAnon-GAAPFY2029$700.00M–NewFeb 25, 2026
Adjusted EBITDAnon-GAAPFY2029$700.00M–NewJan 12, 2026

Guidance vs results

The last range ADMA Biologics gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$510.00M$510.20MΣ4QWithin range

Guidance history

Every forecast ADMA Biologics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 4, 2026Adjusted EBITDAFY2026$275.00MLowered
Nov 4, 2026Adjusted Net IncomeFY2026$180.00MLowered
Nov 4, 2026total revenueFY2026$530.00MLowered
Aug 5, 2026Adjusted EBITDAFY2026$265.00M – $300.00MReaffirmed
Aug 5, 2026Adjusted Net IncomeFY2026$170.00M – $200.00MReaffirmed
Aug 5, 2026total revenueFY2026$530.00M – $560.00MReaffirmed
May 6, 2026Adjusted EBITDAFY2026$265.00M – $300.00MLowered
May 6, 2026Adjusted Net IncomeFY2026$170.00M – $200.00MLowered
May 6, 2026total revenueFY2026$530.00M – $560.00MLowered
Feb 25, 2026Adjusted EBITDAFY2029$700.00MNew
Feb 25, 2026Adjusted EBITDAFY2026$360.00MRaised
Feb 25, 2026Adjusted EBITDAFY2027$455.00MNew
Feb 25, 2026Adjusted Net IncomeFY2026$255.00MRaised
Feb 25, 2026Adjusted Net IncomeFY2027$315.00MNew
Feb 25, 2026total revenueFY2026$635.00MNew
Feb 25, 2026total revenueFY2027$775.00MNew
Feb 25, 2026total annual revenueFY2029$1.10BNew
Jan 12, 2026Adjusted EBITDAFY2027$455.00MNew
Jan 12, 2026Adjusted EBITDAFY2029$700.00MNew
Jan 12, 2026expected Adjusted EBITDAFY2026$360.00MRaised

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases ADMA Biologics filed with the SEC as exhibits to Form 8-K or 6-K

  1. ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update
    Results
  2. ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update
    Results
  3. ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update
    Results
  4. ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV TM to Include Pediatric Immune
    News
  5. ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research
    Update
  6. ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share
    Update
  7. ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results
    Results
  8. ADMA Biologics Announces Preliminary Full Year 2025 Unaudited Total Revenue and Provides Business Update
    Results
  9. ADMA Biologics Realizing the Potential of Specialty Biologicswith Groundbreaking
    Results
  10. ADMA Biologics Announces Third Quarter 2025 Financial Results and Provides Business Update
    Results
  11. ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update
    Results
  12. ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update
    Results
  13. ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process
    News
  14. ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
    Results
  15. ADMA Biologics Realizing the Potential of Specialty Biologicswith
    Update

See a number that looks wrong?